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Abstract: Human molecular cytogenetics integrates the knowledge on chromosome and genome organization at the mo-
lecular and cellular levels in health and disease. Molecular cytogenetic diagnosis is an integral part of current genomic 
medicine and is the standard of care in medical genetics and cytogenetics, reproductive medicine, pediatrics, neuropsy-
chiatry and oncology. Regardless numerous advances in this field made throughout the last two decades, researchers and 
practitioners who apply molecular cytogenetic techniques may encounter several problems that are extremely difficult to 
solve. One of them is undoubtedly the occurrence of somatic genome and chromosome variations, leading to genomic and 
chromosomal mosaicism, which are related but not limited to technological and evaluative limitations as well as multiplic-
ity of interpretations. More dramatically, current biomedical literature almost lacks descriptions, guidelines or solutions of 
these problems. The present article overviews all these problems and gathers those exclusive data acquired from studies of 
genome and chromosome instability that is relevant to identification and interpretations of this fairly common cause of 
somatic genomic variations and chromosomal mosaicism. Although the way to define pathogenic value of all the intercel-
lular variations of the human genome is far from being completely understood, it is possible to propose recommendations 
on molecular cytogenetic diagnosis and management of somatic genome variations in clinical population.  
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INTRODUCTION 
  It is hard to find a cytogeneticist who has not encoun-
tered the problem of interpreting mosaicism. It seems to be 
relatively simple when the majority of cells are abnormal, 
but is extremely difficult in low-level mosaics or in cases of 
detecting cryptic, complex or dynamic mosaic cell popula-
tions. With the introduction of molecular cytogenetic tech-
niques into basic research and diagnostic practice, this has 
become not only a problem of practicing cytogeneticists, but 
a major focus of biomedicine encompassing genomics, 
medical genetics, neuropsychiatry, aging research and repro-
ductive medicine [1]. Since postulating the idea that somatic 
genome variations (SGV) can be a source of human interin-
dividual diversity in health and disease [2, 3], it became evi-
dent that current diagnostic research cannot leave aside this 
issue. 
  There are two main problems surrounding SGV detection 
during molecular cytogenetic diagnosis. The first one is 
technological. The majority of the researchers’ audience is 
unfamiliar with techniques providing for the highest resolu-
tion of SGV evaluation, even though such technologies do 
exist [4]. Additionally, no criteria have been delineated for 
definition of mosaic genome variations [1-4]. The second 
problem is related to interpretation of data on SGV. Succeed-
ing in detecting mosaicism (or SGV) does not necessarily 
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mean diagnostic success. It is usually hard to come to defi-
nite conclusion about results of scoring such a rare event as 
low-level mosaicism. The problem is even more complicated 
because there are no data on benign rates of SGV in humans. 
Therefore, to provide for opportunities regarding molecular 
cytogenetic diagnosis of SGV (mosaicism), additional large-
scale studies and case-reports performed with thorough phe-
notype evaluations and high-resolution single-cell genome 
analyses are required [1-3].  
  This article overviews both problems in the light of new 
developments in molecular cytogenetics. Further, we have 
attempted to define the way it can be managed in molecular 
cytogenetic diagnosis of chromosome imbalances in normal 
and clinical population on the basis of rare data on SGV. 
Additionally, associations between this phenomenon and 
disease are described in order to simplify interpretations of 
mosaicism. Finally, brief troubleshooting and perspectives of 
SGV research in this extent are given to assist researchers in 
molecular diagnosis of mosaicism. 
THE ESTIMATED IMPACT OF SGV ON MOLECU-
LAR CYTOGENETIC DIAGNOSIS 
  To get a view of SGV impact on molecular cytogenetic 
diagnosis, one has to refer to the diseases that are associated 
with. These are malignant [5, 6], brain [3, 7] and autoim-
mune diseases [8] as well as a number of hereditary and 
chromosomal syndromes that are associated with genome or 
chromosome instability [1-3, 7, 9, 10]. Numerous morbid 
conditions are also found to associate with SGV or chromo-
somal mosaicism: spontaneous fetal loss [11, 12], stillbirth, Molecular Cytogenetic Diagnosis and Somatic Genome Variations  Current Genomics, 2010, Vol. 11, No. 6    441 
idiopathic congenital malformations or some clinical features 
of hereditary polygenic disorders [1-3, 11, 13]. Finally, cases 
of complex chromosomal and genomic rearrangements 
(CCRs), copy number variations (CNVs) and monogenic 
syndromes can exhibit SGV [14-18]. Together, it makes an 
appreciable contribution to human morbidity. 
  Molecular cytogenetic diagnosis has become an integral 
part of modern medical care being required for numerous 
fields of medicine [1-4, 19-21]. Molecular cytogenetic tech-
niques are not equally applied for each aforementioned con-
dition. All types of chromosomal imbalances manifesting at 
chromosomal or subchromsomal level (i.e. chromosomal 
syndromes, almost all malignant and some brain diseases, 
fetal losses and idiopathic congenital malformations) 
strongly require molecular cytogenetic techniques in contrast 
to genome/chromosome instability syndromes that are 
caused by gene mutations [2-4, 19-35]. The resolution or 
application need of molecular cytogenetic techniques for 
diagnosis is determined by DNA sequences that are involved 
in genomic rearrangements (for more details see [2-4, 19-
21]). The molecular cytogenetic platforms that have to be 
mentioned in this context are FISH (fluorescence in situ hy-
bridization) and CGH (comparative genomic hybridization) 
or, more precisely, array CGH. However, the most applica-
ble methods for detection of SGV are based on FISH (for 
review see [2, 4]). Table 1 gives an overview of conditions 
associated with SGV that requires molecular cytogenetic 
diagnosis. 
  As one can see, morbid conditions, which are in need of 
molecular cytogenetics, are either those caused by subtle 
genomic rearrangements (detected at molecular level) or 
those associated with mosaicism in a proportion of cases. 
These are more commonly manifested as cases of chromo-
somal mosaicism [1]. Syndromes of chromosome instability 
exhibit changes in chromosomal numbers and/or structure in 
somatic cells, which can be defined as SGV or somatic 
chromosomal mosaicism [10, 36, 37]. However, being of 
monogenic nature, many of these diseases are usually diag-
nosed via molecular genetic techniques (sequencing, PCR). 
Therefore, a molecular cytogenetic technique applied in this 
instance has to provide simultaneously for high resolution 
and for single-cell analysis [4]. The next part of our brief 
review addresses this as well as other issues concerning 
technical aspects of SGV detection by molecular cytogenetic 
techniques. 
THE FIRST PROBLEM: TECHNICAL POTENTIAL 
OF MOLECULAR CYTOGENETICS FOR SGV DE-
TECTION 
  Recently, a series of reviews has addressed the level of 
excellence in molecular cytogenetics with respect to identifi-
cation of SGV [1-4, 21, 38]. It allows us to skip wide discus-
sions about technological aspects of molecular cytogenetic 
analyses of human chromosomes for detection of mo-
saicism/SGV. Nevertheless, we would like to point some 
aspects relevant to the diagnosis. Firstly, we have to mention 
Table 1.  Diseases and Morbid Conditions Associated with SGV Requiring Molecular Cytogenetic Diagnosis 
Disease/Morbid Condition  Platforms for Diagnosis 
Necessity of Molecular Cytogenetic 
Diagnosis* 
Key Refs 
Spontaneous abortions (10-15 wks)  FISH  +++  [12] 
Abnormal prenatal development (prenatal diagnosis) 
FISH 
CGH** 
+++ [11,  22-24] 
Chromosomal syndromes/non-specific causal abnormali-
ties 
FISH 
CGH 
+++ 
[1-4, 11, 19-
21] 
Diseases caused by CNVs 
CGH 
FISH 
+++ [25] 
Idiopathic congenital malformations 
Developmental delays 
FISH 
CGH 
+++  [2, 11, 19-21] 
Idiopathic learning disability  
FISH 
CGH 
+++  [7, 11, 26] 
Cancer 
FISH 
CGH 
+++  [2, 4-6, 19-21] 
Autism 
FISH 
CGH 
++ [7,  27-30] 
Schizophrenia 
FISH 
CGH 
+ [31-33] 
Autoimmune diseases  FISH  +  [8] 
Monogenic syndromes  Fiber FISH  +  [34, 35] 
* — the level of necessity is defined as indispensable (+++), method of choice (++), rarely applied (+); ** — array CGH included. 442    Current Genomics, 2010, Vol. 11, No. 6  Vorsanova et al. 
that it is really possible to achieve the resolution as high as 
1% of cells affected by SGV or even lower [4, 28, 36-42]. 
The scoring of such a rare event as low-mosaicism is granted 
by approaches that include several molecular cytogenetic 
FISH-based techniques. These analyses possess the potential 
to embrace large cell populations. The latter means such as-
says to be more likely interphase than metaphase ones. For 
analyzing the majority of cell types, this is the unique possi-
bility. Here, it is to note the existence of numerous draw-
backs of the classical interphase FISH protocols: numerous 
genome behavioral peculiarities (replication, high-ordered 
chromosome organization in interphase nuclei) mimic chro-
mosome number/structure variations (SGV), chromosomal 
heteromorphisms, or simply lack of visualization of whole 
chromosomes [4, 36, 43-47]. To get rid of these technical 
problems, it has been proposed to use in parallel multiprobe 
interphase FISH (simultaneous multitarget), digital analyses 
of FISH data (QFISH) and interphase multicolor banding 
technique for visualization of whole chromosomes in non-
dividing cells [3, 12, 29, 36-44, 46, 47]. Although the ap-
proach has been exclusively applied to basic research, it has 
the potential to be a powerful diagnostic tool [1-4, 21]. 
  Regardless developments in molecular cytogenetics that 
allow to analyze either interphase nuclei or DNA isolated 
from any cell type, the major part of cases requiring cytoge-
netic evaluation are firstly assessed through metaphase-
analysis-based techniques [4, 21, 48]. This is the source of 
another, yet unresolved, problem — discrepancies between 
metaphase and interphase molecular cytogenetic analyses. 
To date, no clear explanation has been found to understand 
the basis and meaning of such differences. Eventually, one 
can see it looking through those few papers describing rec-
ommendations concerning detection of mosaicism in clinical 
cytogenetic practice or basic SGV research [2, 3, 12, 29, 36-
42, 49-51]. Despite of the same ultimate aim referred to un-
covering the presence of mosaicism, these guidelines differ 
significantly by technological requirements and the ways of 
the development. Taking into account the lack of major 
technological impediments, the problem of “mosaicism 
guidelines” correlation is the essential technical one. 
THE SECOND PROBLEM: WHAT DOES SGV 
MEAN? 
  As previously noted, the confirmation of mosaicism (es-
pecially, low-level mosaicism) in an individual leads to the 
problem of the interpretation. In other words, pathogenicity 
of mosaicism or SGV is always a matter of conjecture. It 
seems to be easier when abnormal cell lines are prevalent, 
but the borderline between pathogenic condition and benign 
variation is undetermined [3]. This is further complicated 
inasmuch as SGV is more commonly observed in a clinical 
population and is known to be associated with malignization 
[1-15, 25-29, 31, 32, 35-38, 42, 48]. Due to a higher fre-
quency, the best studied in this context is aneuploidy or ane-
uploidization of somatic tissues [1-4]. Analyses of ane-
uploidy effect on transcriptional activity of the whole cellu-
lar genome yielded contradictory results, showing, however, 
that aneuploidization should possess a global negative effect 
on cellular physiology via transcriptional changes [52, 53]. 
Studies implicating clinical population, aneuploidy syn-
dromes or chromosomally instable tissues (disease models) 
have shown that deleterious effects are only produced in 
cases of either chromosome-specific increase of aneuploidy 
rates or a global rise of spontaneous chromosomal mutations. 
Background (sporadic) aneuploidy is more likely to be a 
result of natural (benign) SGV without appreciable effects 
[2, 3, 7, 10, 27-29, 32, 36-42, 54]. 
  Since the data on SGV were rarely confirmed to be 
pathogenic, it is better to consider such genomic variations 
rather a neutral or a susceptibility factor than a causative 
genetic abnormality. Unless repeatedly described in the lit-
erature, low-level mosaics or SGV cannot be defined as dis-
ease-causing mutations. It does not mean that some disease 
with strong genetic background do not require molecular 
cytogenetic diagnosis respecting the presence of SGV, but 
suggests more critical assessment as to constitutional ge-
nomic rearrangements. In summary, even though several 
lines of evidence suggest an association between low-level 
mosaics, SGV and an abnormal phenotype, their clinical 
interpretation and diagnostic value seem to require additional 
case-control studies. 
SOLUTIONS AND RECOMMENDATIONS 
  Molecular cytogenetic diagnosis of SGV means: (i) scor-
ing of rare events; (ii) possible lack of reproducibility; (iii) 
different approaches may not yield similar results; (iv) detec-
tion of SGV does not imply guaranteed diagnostic success. 
Together, it makes an impression that the solution of all the 
difficulties surrounding this task is hardly possible. Notwith-
standing, either separate or sequential application of numer-
ous molecular cytogenetic techniques gives extremely high 
resolution for scoring single-cell rare events [1-3, 12, 36-42]. 
The irreproducibility is essentially produced by analysis of 
cells cultivated in vitro (scoring of insufficient number of 
metaphase cells or combined metaphase/interphase analyses) 
[4]. Therefore, application of interphase molecular cytoge-
netic approaches using uncultured cell populations can help 
to escape from such situations. This is partially confirmed by 
analysis of SGV in neuropsychiatric diseases [27-29, 32, 36, 
37, 40-47]. These studies as well as the analysis of unaf-
fected somatic tissues have also generated an integrated ap-
proach towards uncovering SGV affecting 1% of cells or 
lower [2-4, 7, 29, 36, 37, 40-47]. Thus, SGV detection meets 
no more technological problems than those associated with 
selecting benchmarks for evaluations of mosaicism in a 
given cell population. Although it still does not answer the 
question concerning the pathogenicity, the application of 
specified guidelines allows to make evaluations of mo-
saicism occurrence in large cohorts with respect to its bio-
medical meaning. Moreover, these data would give the pos-
sibility to determine the real amount of abnormal cells in an 
individual regardless any effect it can produce. Table 2 
summarizes experimentally tested recommendations for de-
tection of mosaicism (SGV). 
  The recommendations presented in Table 2 are unlikely 
to be combined for producing unified guidelines. The latter 
is mainly caused by different techniques applied for the de-
velopment and area of application. Therefore, to solve the 
problem, a large-scale study of several cell populations ac-
quired from different somatic human tissues appears to be 
strongly required. Nonetheless, before such data will be Molecular Cytogenetic Diagnosis and Somatic Genome Variations  Current Genomics, 2010, Vol. 11, No. 6    443 
available, one has to follow these recommendations or to 
develop new ones on basis of original molecular cytogenetic 
investigation. 
  Despite of difficulties in interpreting results, there are 
positive associations between SGV and several morbid con-
ditions [1-3, 7, 12, 29, 36, 37, 40-47, 54]. Since no other data 
is available to solve the problem of interpretation multiplic-
ity, we found pertinent to mention all the pathologic condi-
tions associated with SGV.  
  SGV manifesting as chromosome-specific mosaicism or 
instability are common among spontaneous abortions in the 
first trimester [12]; chromosomal, microdeletion/duplication 
and CNV-associated syndromes [3, 7, 11, 13, 25, 45, 48, 54]; 
chromosome instability syndromes (ataxia-telangiectasia) 
[37]; supernumerary marker chromosomes [55-57]; idio-
pathic learning disability with/without congenital malforma-
tions [1-4, 7, 58, 59]; autism [27-29]; schizophrenia [31, 32, 
42]; autoimmune diseases [8]; Alzheimer’s disease [36]. 
This type of SGV is also a susceptibility factor for female 
germline aneuploidization leading to trisomic conceptuses 
(trisomy of chromosome 21) [60] and a “license to live” for 
males with X-linked dominant diseases (i.e. Rett syndrome) 
who need an additional chromosome X to escape intrauterine 
lethality [61]. CCRs are primarily associated with reproduc-
tion problems [14, 15, 17] and more rarely with learning 
disability and congenital malformations [17]. SGV manifest-
ing as increased levels of genome/chromosome instability, 
spontaneous chromosomal mutations or aneuploidization are 
observed in cancers or cancer-predisposition syndromes [2, 
5, 6, 9, 10, 13]; chromosome instability syndromes (ataxia-
telangiectasia) [9, 10, 36, 37]; idiopathic learning disability 
with/without congenital malformations [1-4, 7, 58, 59]; 
schizophrenia [31, 32, 42]; diseases of pathologi-
cal/accelerating aging [10]. Another important diagnostic 
problem related to molecular cytogenetics of SGV is dy-
namic mosaicism. The latter is indeed relatively easy to 
solve: a series of high-resolution metaphase/interphase mo-
lecular cytogenetic techniques has to be used [62]. Finally, it 
is supposed that numerous other diseases could be associated 
with SGV [1-4].  
THE UPDATED SCHEME FOR MOLECULAR CY-
TOGENETIC DIAGNOSIS 
  Taking into account all the developments in the field of 
molecular cytogenetics as well as main characteristics of 
more popular FISH-, CGH- and array-CGH-based tech-
niques [1-4, 19-21, 26, 34-47, 63, 64], we have made an at-
tempt to propose an original diagnostic scheme that include 
the analyses of mosaicism and SGV. Fig. (1) depicts the pro-
posed scheme of molecular cytogenetic diagnosis taking into 
account all the points discussed herein. It is noteworthy that 
previous schemes of molecular diagnosis in the available 
biomedical literature have never addressed the detection of 
SGV manifested at chromosomal or subchromosomal level 
(chromosomal mosaicism). Together, one can get an idea of 
the huge amount of “diagnostic work” that has to be per-
formed for high-resolution diagnosis of the mosaicism. Ad-
ditionally, “starting techniques” have to be those providing 
for whole genome screen (i.e. cytogenetic banding analyses, 
standard (high-resolution) CGH or array CGH). However, it 
is to keep in mind that CGH-based techniques are poorly 
applicable for low-level mosaicism and SGV detection in 
large cell populations [4]. FISH-based techniques (multi-
probe FISH and quantitative FISH) allow targeted single-cell 
analysis of genomic loci in huge cell populations and only 
multicolor banding analysis depicts whole chromosomes in 
non-dividing cells (for more details see Fig. 1 and [1-4, 21, 
38]). We suggest our proposal to lead to more effective mo-
lecular cytogenetic diagnosis in cases of mosaicism or SGV. 
CONCLUDING REMARKS 
  It is hard not to recognize that current biomedical diag-
nostic research and practice are more focused on constitu-
tional genomic rearrangements that are easier to interpret and 
to use for disease-association studies [63, 64]. As a result, 
numerous human morbid conditions are postulated to require 
Table 2.  Recommendations for Detection of Chromosomal Mosaicism and SGV 
Source  Area of Application  Detection Rate  Amount of Cells to Score 
Hsu et al., 1992 [49]  Prenatal diagnosis by cytogenetic techniques  0.5% (1 cell)*  200 
Caudill et al., 2005 [50]  Prenatal diagnosis by cytogenetic techniques   15%  15-30 
Vorsanova et al., 2005 [12]  Fetal aneuploidy by molecular cytogenetic techniques  <5%  300-500 
Yurov et al., 2005 [39]; 2007 [29, 41]; 
2008 [42]; Iourov et al., 2006 [3]; 
2009 [38]. 
Chromosome abnormalities or SGV by molecular 
cytogenetic techniques 
<0.1% 1000-10000 
Iourov et al., 2009 [36, 37] 
Chromosome instability or SGV by molecular cytoge-
netic techniques 
0.1-1% 1000-10000 
Iourov et al., 2006 [40]; 2009 [38] 
Chromosome abnormalities or SGV by molecular 
cytogenetic techniques 
<0.5%  
(1 cell)* 
>100 
Wiktor et al., 2009 [51]  Sex chromosome aneuploidy by cytogenetic techniques 
>3%  
(1 cell) 
20-30 
* — pseudomosaicism. 444    Current Genomics, 2010, Vol. 11, No. 6  Vorsanova et al. 
molecular cytogenetic diagnosis by array-CGH-based tech-
niques [17, 20, 24-26, 30, 33, 54, 63, 64], which operate with 
total DNA isolated from a pool of cells and are inapplicable 
for studying the majority of mosaicism types and SGV [1-4, 
7, 19, 21, 23, 27-29, 36-42, 47, 54, 57, 62]. Therefore, high-
resolution whole genome screen is not the complete diagnos-
tic solution for current molecular diagnosis. SGV require a 
specific set of molecular cytogenetic techniques to be diag-
nosed (Fig. 1). Thus, to provide a highly technological medi-
cal care (at least, in diagnostic terms), these have to be intro-
duced.  
  The problems that surround diagnosis of SGV and mo-
saicism remain to be thoroughly addressed by large-scale 
forthcoming studies targeted at definition of causative 
amount of abnormal cells per analysis, local effect on cellu-
lar/tissular physiology with respect to potential effects on the 
whole organism, correlations between metaphase and inter-
phase analyses in cases of molecular cytogenetic diagnosis 
of chromosome abnormalities. To this end, we would like to 
point out that current molecular cytogenetics possess tools 
for high-resolution detection of SGV, which have to be used 
for uncovering the biomedical significance of this common 
and, probably, most mysterious type of genomic variations. 
  Hopefully, further research will be able to solve this 
complex and widely relevant problem. 
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